Skip to content
QurAlisQurAlis
  • About UsExpand
    • About QurAlis
    • Leadership
    • Board of Directors
    • Advisors
    • Partners & Investors
    • Contact Us
  • PlatformsExpand
    • QR43 Platform™
    • FlexASO™ Platform
  • Pipeline
  • PatientsExpand
    • ALS Patients
    • A Message of Hope
  • NewsExpand
    • Press Releases
    • Presentations and Publications
  • Careers
QurAlisQurAlis

Press Releases

Home
News
Press Releases

September 6, 2023

QurAlis to Present Data Showing Link Between TDP-43 Pathology and Role of UNC13A in Neuronal Biology Related to ALS and Other Neurodegenerative Diseases

July 11, 2023

QurAlis Receives Clinical Trial Authorisation (CTA) in the U.K. for QRL-201, a First-in-Class STATHMIN-2 Precision Therapy for ALS

June 27, 2023

QurAlis and Unlearn Announce Collaboration to Accelerate and Optimize ALS Clinical Trials With Generative Artificial Intelligence Technologies

June 8, 2023

QurAlis’ FlexASOs Show High Potency and Improved Safety Over Standard ASOs

June 6, 2023

QurAlis Receives Clinical Trial Authorisation (CTA) in European Union (EU) for QRL-201, a First-in-Class STATHMIN-2 Precision Therapy for ALS

June 1, 2023

QurAlis to Participate in Upcoming Investor Conferences in June

April 6, 2023

QurAlis Announces First Patient Dosed With QRL-201, a First-in-Class STATHMIN-2 Precision Therapy for ALS

March 20, 2023

QurAlis Reveals Newest Program Targeting UNC13A RNA Mis-splicing Incorporating its FlexASO™ Platform

March 9, 2023

QurAlis Closes $88 Million Series B Financing to Advance Precision Medicines for Neurodegenerative Diseases

January 5, 2023

QurAlis Announces First-in-Human Dose in Phase 1 Clinical Trial of QRL-101, a First-in-Class Kv7 Precision Therapy for ALS

December 8, 2022

QurAlis Receives Health Canada Clinical Trial Application Authorization for QRL-201, a First-in-Class STATHMIN-2 Precision Therapy for ALS

September 13, 2022

QurAlis to Present at 22nd Annual Biotech in Europe Forum

July 27, 2022

QurAlis to Present at H.C. Wainwright Private Company Showcase

June 21, 2022

QurAlis Announces the Appointment of Anne C. Whitaker as Chair of the Board

May 25, 2022

QurAlis Presents at ALS Drug Development Summit 2022

March 22, 2022

QurAlis to Present at H.C. Wainwright Gene Therapy and Gene Editing Virtual Conference

March 15, 2022

QurAlis Presents Data About STATHMIN-2 Role in Neuronal Disease Biology and TDP-43 Biomarker Identification at AD/PD™ 2022

February 8, 2022

QurAlis Hires Key Regulatory Affairs, Clinical Operations, and Global Supply Chain Management Experts to Support Strategic Objectives

January 3, 2022

QurAlis to Present at H.C. Wainwright BioConnect 2022 Virtual Conference

December 22, 2021

QurAlis Announces Publication in Molecular Biology of the Cell of Next Generation Drug Screening Platform for ALS Developed by Company Founders

December 6, 2021

QurAlis Presents New Data Confirming Role of STATHMIN-2 in Neuronal Disease Biology at 32nd International Symposium on ALS/MND

November 18, 2021

QurAlis to Present at 33rd Annual Piper Sandler Virtual Healthcare Conference

September 14, 2021

QurAlis Announces Development Candidate for ALS Targeting STATHMIN-2

June 8, 2021

Cell Reports Publishes Discovery Data Supporting the Importance of Ion Channel, Kv7.2/7.3 as a Therapeutic Target in ALS

May 26, 2021

QurAlis Boosts World-Class Leadership Team with Addition of Three New Members

February 2, 2021

QurAlis Continues to Expand Leadership Team with Two Key Hires

December 10, 2020

QurAlis’ Selective Kv7 Opener, a Drug Candidate for ALS, Demonstrates up to 20-Fold Increase in Potency and Dramatic Reduction in Side Effects Compared to Retigabine in Preclinical Models

December 2, 2020

QurAlis to Present Data on Two Precision Medicine Programs (Kv7 and TBK1) at MNDA 31st International Symposium on ALS/MND

October 29, 2020

QurAlis Announces Appointment of new Chief Medical Officer and Formation of Clinical Advisory Board

July 1, 2020

QurAlis Announces Agreement to Strengthen ALS Pipeline

May 13, 2020

QurAlis raises $42 Million Series A Financing to Develop New Therapies for Amyotrophic Lateral Sclerosis (ALS)

April 5, 2018

QurAlis Launches with Seed Funding from MPH, Amgen and Alexandria, united in the fight to cure ALS

December 15, 2017

QurAlis has won the Amgen Golden Ticket at LabCentral

100 Cambridgepark Drive, 5th Floor
Cambridge, MA 02140, USA
617-362-7157
info@quralis.com

Twitter Linkedin
  • About Us
  • Platforms
  • Pipeline
  • Patients
  • News
  • Careers
  • About Us
  • Platforms
  • Pipeline
  • Patients
  • News
  • Careers
© 2021 QurAlis Corporation | Privacy Policy | Terms of Use
  • About Us
    • About QurAlis
    • Leadership
    • Board of Directors
    • Advisors
    • Partners & Investors
    • Contact Us
  • Platforms
    • QR43 Platform™
    • FlexASO™ Platform
  • Pipeline
  • Patients
    • ALS Patients
    • A Message of Hope
  • News
    • Press Releases
    • Presentations and Publications
  • Careers